Alpine Immune Sciences (NASDAQ:ALPN) Receives Hold Rating from TD Cowen

TD Cowen reaffirmed their hold rating on shares of Alpine Immune Sciences (NASDAQ:ALPN) in a research report sent to investors on Tuesday, Benzinga reports.

ALPN has been the topic of a number of other reports. Wedbush cut shares of Alpine Immune Sciences from an outperform rating to a neutral rating in a report on Thursday, April 11th. Guggenheim started coverage on Alpine Immune Sciences in a research report on Tuesday, April 9th. They issued a buy rating and a $55.00 price objective for the company. Oppenheimer reissued an outperform rating and set a $44.00 target price (up from $33.00) on shares of Alpine Immune Sciences in a report on Tuesday, March 19th. Morgan Stanley restated an equal weight rating and issued a $65.00 price target (up previously from $47.00) on shares of Alpine Immune Sciences in a research note on Thursday, April 11th. Finally, HC Wainwright cut shares of Alpine Immune Sciences from a buy rating to a neutral rating in a research report on Thursday, April 11th. Eight equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of Hold and an average target price of $50.33.

Alpine Immune Sciences Stock Up 0.2 %

NASDAQ:ALPN opened at $64.55 on Tuesday. Alpine Immune Sciences has a twelve month low of $6.71 and a twelve month high of $64.57. The firm has a market capitalization of $4.23 billion, a price-to-earnings ratio of -100.86 and a beta of 1.14. The stock’s 50 day moving average price is $40.09 and its two-hundred day moving average price is $24.80.

Alpine Immune Sciences (NASDAQ:ALPN) last released its earnings results on Monday, March 18th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.47. Alpine Immune Sciences had a negative net margin of 54.66% and a negative return on equity of 15.54%. The business had revenue of $30.85 million during the quarter, compared to analysts’ expectations of $6.90 million. As a group, analysts anticipate that Alpine Immune Sciences will post -1.74 earnings per share for the current year.

Institutional Trading of Alpine Immune Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of the business. American International Group Inc. grew its position in shares of Alpine Immune Sciences by 2.2% during the 4th quarter. American International Group Inc. now owns 16,185 shares of the biotechnology company’s stock worth $308,000 after purchasing an additional 343 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Alpine Immune Sciences by 1.3% in the third quarter. Bank of New York Mellon Corp now owns 92,723 shares of the biotechnology company’s stock valued at $1,062,000 after buying an additional 1,216 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Alpine Immune Sciences by 745.5% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,488 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 1,312 shares in the last quarter. Royal Bank of Canada boosted its stake in shares of Alpine Immune Sciences by 99.1% in the second quarter. Royal Bank of Canada now owns 2,642 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 1,315 shares during the period. Finally, JPMorgan Chase & Co. grew its position in Alpine Immune Sciences by 23.4% during the first quarter. JPMorgan Chase & Co. now owns 8,947 shares of the biotechnology company’s stock worth $80,000 after buying an additional 1,697 shares in the last quarter. Institutional investors and hedge funds own 75.17% of the company’s stock.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.